Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.
- DOI
- 10.1093/ecco-jcc/jjaf005
- Published
- 2025-01-01
- Container
- J Crohns Colitis
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ecco-jcc/jjaf005,
title = {Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.},
author = {Panaccione R and Louis E and Colombel JF and D'Haens G and Peyrin-Biroulet L and Dubinsky M and Takeuchi K and Rubin DT and Kalabic J and Chien KB and Chen S and Cheng L and Zhang Y and Duan WR and Vladea R and Hecht PM and Morisset P and Schreiber S and Ferrante M.},
year = {2025},
journal = {J Crohns Colitis},
doi = {10.1093/ecco-jcc/jjaf005},
url = {https://doi.org/10.1093/ecco-jcc/jjaf005}
}RIS
TY - JOUR TI - Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. AU - Panaccione R AU - Louis E AU - Colombel JF AU - D'Haens G AU - Peyrin-Biroulet L AU - Dubinsky M AU - Takeuchi K AU - Rubin DT AU - Kalabic J AU - Chien KB AU - Chen S AU - Cheng L AU - Zhang Y AU - Duan WR AU - Vladea R AU - Hecht PM AU - Morisset P AU - Schreiber S AU - Ferrante M. PY - 2025 JO - J Crohns Colitis DO - 10.1093/ecco-jcc/jjaf005 UR - https://doi.org/10.1093/ecco-jcc/jjaf005 ER -
APA
R, P., E, L., JF, C., G, D., L, P., M, D., K, T., DT, R., J, K., KB, C., S, C., L, C., Y, Z., WR, D., R, V., PM, H., P, M., S, S., & M., F. (2025). Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.. J Crohns Colitis. https://doi.org/10.1093/ecco-jcc/jjaf005
Source records
- europe-pmc · retrieved 2026-09-26T20:07:28.043Z